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Risk management planAbstract Pharmacovigilance plays an important role in ensuring that patients are receiving safe
drugs. In Saudi Arabia, Saudi Food and Drug Authority, health institutions, marketing authoriza-
tion holders and healthcare professional are involved in pharmacovigilance activities regardless of
the level of the involvement. Although pharmacovigilance is well established in developed nations
and it is considered a new concept in Saudi Arabia. It is a collective effort from various stakeholders
to make pharmacovigilance successful toward promoting safe and effective use of medicines among
the population. However, the practice of pharmacovigilance still needs more attention especially
from marketing authorization holders and healthcare professionals. The aim of this review was
to describe the current situation of pharmacovigilance in Saudi Arabia and the activities that have
been conducted by the stakeholders.
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Pharmacovigilance plays an important role in ensuring
patients’ drug safety. In the Kingdom of Saudi Arabia
(KSA), it is considered a new concept and all stakeholders
are still not fully functioning and applying all pharmacovigi-
lance tasks. As this topic is considered new in Saudi Arabia
and even in the region, pharmacovigilance has been strongly
initiated by the Saudi Food and Drug Authority (SFDA) as
there is a large department performing pharmacovigilance
activities. There has been an increase in the number of reports
over a short period of time. Also, other pharmacovigilance
activities, such as periodic safety update, reports review and
risk management plans have been performed. Other stakehold-
ers have also started to implement pharmacovigilance activi-
ties; however, there is a variation in the level of
implementation.
This review describes the current situation of pharmacovig-
ilance in the Kingdom of Saudi Arabia and the activities being
conducted by these stakeholders.
2. The healthcare system in Saudi Arabia
The healthcare system in the kingdom is under the jurisdiction
of the Ministry of Health. The Ministry of Health offers
healthcare services to the public through its complex organiza-
tional structures comprising 244 hospitals, 2037 healthcare
centers, referral hospitals, security forces healthcare institutes
with medical services, and so on. Saudi Arabia also boasts
its own Red Crescent Authority, which undertakes an impor-
tant and efficacious role in providing emergency services at
the pre-hospitalization stage, either at accident sites or while
transporting patients to the hospitals. In addition, this body
serves a unique task of handling pilgrims during Hajj and
Umrah at the holy places of Mecca and Medina.
Healthcare services in the kingdom are a highly sensitive
area of development that needs continuous improvements.
Hence, the Saudi Government deems healthcare services a pri-
ority, as is evident from the WHO ranking of the Saudi health-
care system at 26 among 190 countries all over the world
(Almalki et al., 2011). Despite the untiring efforts of the gov-
ernment, there are still several components that require to be
addressed such as a shortage of qualified healthcare profes-
sionals, changing patterns of disease, a poor health informa-
tion system, the under-utilization of electronic health
strategies, low Adverse Drug Reactions (ADRs) reporting
and so forth (Almalki et al., 2011; Khan et al., 2012). ADRPlease cite this article in press as: Alshammari, T.M. et al., Pharmacovigilance sys
10.1016/j.jsps.2016.09.008reporting through pharmacovigilance is gaining more atten-
tion in recent times. The consequences of ADRs are detrimen-
tal; however, they can be prevented if detected on time. Thus,
the important aspect is their detection and minimization
requiring a collective effort from all healthcare professionals
including physicians, pharmacists, and nurses. In recent days,
the professional role of pharmacists is gaining more recogni-
tion in the healthcare system as they are more involved in
patient care (Chisholm-Burns et al., 2010; Kaboli et al.,
2006). Thus, the concerned authorities desire a greater contri-
bution from pharmacists to report ADRs, improve patient’s
health, and improve their economic outcomes (Hume et al.,
2012; Sweis and Wong, 2000; van Grootheest et al., 2004).
3. Stakeholders in pharmacovigilance
The use of medicines is vastly increasing due to growing pop-
ulations, the emergence of various health complications and an
increased health consciousness among the people globally.
Thus, it is important to assure the safe and effective use of
medicines. This demands collective and ongoing efforts from
different stakeholders such as pharmaceutical manufacturers,
Government drug regulatory authorities (e.g. SFDA), health-
care professionals (e.g. physicians, pharmacists, nurses,
paramedical staff, and so on), patients or patient parties, con-
tract research organizations, hospitals, and clinics where clini-
cal trials are conducted (Davies, 2015).
3.1. Saudi Food and Drug Authority (SFDA)
The Government of Saudi Arabia established the Saudi Food
and Drug Authority in 2003. The prime objective of this regu-
latory authority was to regulate safe and effective use of
medicines, medical devices, food items and even cosmetics in
the kingdom (Saudi Food and Drug Authority, 2013a).
The SFDA consists of three main sectors: food, drug, and
medical devices. Each sector has its own distinct role based
on its nature of work (Saudi Food and Drug Authority,
2013b). As this paper is about the safety issues of medicines,
we would like to focus on the role of the drug sector of the
SFDA. Medicines have become an integral part of our lives
for treating simple to complex health complications. However,
lack of proper use of medicines and monitoring the conse-
quences due to them are vital issues. Thus, SFDA realized
the necessity to establish a separate unit, called the National
Pharmacovigilance Center (NPC) to monitor the safety issues
of medicines (Saudi Food and Drug Authority, 2013c). NPCtem in Saudi Arabia. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
Figure 1 Saudi Food and Drug Authority ADR-1 paper reporting form for healthcare professionals.
Pharmacovigilance system 3plays an important role in the detection of ADRs, their assess-
ment and prevention, and this unit will ultimately expand to be
a large executive directorate concerning pharmacovigilancePlease cite this article in press as: Alshammari, T.M. et al., Pharmacovigilance sys
10.1016/j.jsps.2016.09.008and crisis management (Saudi Food and Drug Authority,
2013c). Originally, the word ‘pharmacovigilance’ is derived
from the Greek word ‘pharmacon,’ which means ‘drug,’ andtem in Saudi Arabia. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
Figure 2 The online portal to the pharmacovigilance electronic reporting services.
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watch’ (Center, 2009; Soni and Kesari, 2014). WHO defines
pharmacovigilance as ‘the science and activities relating to
the detection, assessment, understanding, and prevention of
adverse effects or any other drug-related problem’ (World
Health Organization, 2014a). The concern of pharmacovigi-
lance is not limited to allopathic medicines but also covers
herbal, traditional, and complementary medicines; blood prod-
ucts; vaccines; and medical tools and devices (World Health
Organization, 2014b). Pharmacovigilance not only reduce the
ADRs but also shortens the duration of stays in hospital,
lessens economic burdens, and reduces mortality (World
Health Organization, 2014c).
Despite the NPC’s efforts to make available the reporting
of ADRs online as well as on paper (Figs. 1 and 2 as exam-
ples), the under-reporting of ADRs by the public and HCPs
is still prevalent. Thus, it requires collective and continued
efforts to encourage ADR reporting. The online reporting
form is available through this Web site, https://ade.sfda.gov.
sa/ (Saudi Food and Drug Authority, 2013d).
3.1.1. Structure and duties of the Vigilance and Crisis
Management (VICM) Executive Directorate
The SFDA realized the need for further strengthening pharma-
covigilance. Therefore, it was decided to make an executive
directorate, i.e. the Vigilance and Crisis Management (VICM)
Executive Directorate with a more specialized function.
The VICM functions to follow up both marketed drugs and
the ongoing assessment of the safety and quality of pharma-
ceuticals, side effects, and medication errors. The directorate
also acts to prevent the risk of occurrence of a crisis of phar-Please cite this article in press as: Alshammari, T.M. et al., Pharmacovigilance sys
10.1016/j.jsps.2016.09.008maceutical products and manage this, when possible, by taking
appropriate standard actions in cooperation with other depart-
ments in the pharmaceutical sector.
The VICM is divided into the National Pharmacovigilance
and Drug Safety Center (NPC), medication errors, and crisis
management. Based on personal communication with SFDA,
the VICM has been modified to include the benefit part of
its tasks; therefore, the name will no longer be VICM. How-
ever, this information was not updated on the Web site or
other authentic source of information (Saudi Food and Drug
Authority, 2013c).
3.1.2. WHO Monitoring Center (Uppsala Monitoring Center)
and the NPC
The Uppsala Monitoring Center (UMC), which is a part of the
WHO, receives ADR reports from the countries which have
subscribed, and since its establishment in 1978, report’s num-
bers have reached around 12 million (World Health
Organization, 2016). So far, there are 123 countries registered
as members with the UMC, and the SFDA became the 92nd
member of the UMC in the same year as launching the VICM
at the SFDA (Center, 2009; World Health Organization,
2016).
Participating in the UMC entails several obligations for the
SFDA and also various advantages for the SFDA, such as per-
forming signal detection using the VigiBase system, which
includes around 12 million reports (Vigibase, 2016). This helps
to study any alarming signals that occur in Saudi Arabia. Also,
there are other advantages such as an annual gathering to dis-
cuss methods to improve pharmacovigilance activities within
the participating countries.tem in Saudi Arabia. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
Pharmacovigilance system 53.1.3. SFDA post-marketing activities
The strategic plan of SFDA is to set up the NPC. It sees the
crucial importance of constructing a robust infrastructure for
the NPC, in the form of strengthening the lines of staff and
ensuring that the staff are qualified for the job; they are
expected to have the necessary and relevant qualifications in
addition to expertise. The NPC has prepared well-formulated
reporting forms and a reliable database. These forms include
forms for healthcare professionals and patients to submit
any ADR. In addition, there are report forms for drug quality
defects (Saudi Food and Drug Authority, 2013d; Wilbur,
2013). The establishment of an advisory committee is also
vital, where it can advise the NPC on any growing issues or
draw its attention towards ADR reports and similar cases
(Saeed, 2014). More importantly, the NPC is expected to serve
as the intermediary between hospitals and the reporting sys-
tem, so that all issues that arise among hospitals can be
addressed and steps for prevention can be laid out. However,
before this can happen, the NPC helps all hospitals to be able
to submit ADR reports.
In a broad sense, the most important task is to make people
aware about ADRs, pharmacovigilance and people’s contribu-
tion. Therefore, VICM has facilitated the reporting of ADRs
through various ways such as verbal, online or paper, tele-
phone, fax, and email (Saudi Food and Drug Authority,
2013d).
The SFDA also promotes ADR reporting in the KSA so
that regulatory action can be taken based on the ADRs
received. It also provides information to physicians, pharma-
cists, and other healthcare professionals on ADRs. Regarding
report statistics, 76,949 reports were received in 2014. Of the
76,949 reports received, 75,486 reports (98.1%) were ADRs,
697 (0.9%) were medication errors, and the remaining 770
(1%) were reports of poor quality. However, reports from
Marketing Authorization Holders (MAHs) show an increasing
trend. 73,067 reports (95%) were received from drug compa-
nies, 2856 reports (3.71%) were received from hospitals and
only 131 (0.17%) reports were received from the general public
(Saeed, 2014).
3.1.4. Periodic Safety Update Reporting (PSUR) and
pharmacovigilance actions
The periodic safety update reporting (PSUR) was started in
the early 1990s by the Council for International Organizations
of Medical Sciences (CIOMS) and was widely accepted and
implemented in many parts of the world including the King-
dom of Saudi Arabia (Klepper, 2004). A PSUR is a report
that provides an evaluation of the benefit-risk balance of a
medicine, which is submitted by MAHs to the SFDA in the
ICH E2C(R2) Format (Klepper, 2004; Saeed, 2014). PSURs
are considered as a valuable resources for pharmacovigilance
data for any regulatory agency. The SFDA has received 817
PSURs; of them, 277 were reviewed, and 71 actions were
taken for safety reasons. Those actions ranged from labeling
updates to submission of risk management plans (RMP)
(Saeed, 2014).
3.1.5. Electronic systems
At the planning stage of establishing the pharmacovigilance
center, setting up an electronic system was one of the major
tasks of the SFDA. Healthcare professionals established anPlease cite this article in press as: Alshammari, T.M. et al., Pharmacovigilance sys
10.1016/j.jsps.2016.09.008electronic reporting form for their use. However, there were
complaints that the form was too long. Therefore, a new elec-
tronic version of a four steps – similar to the United States
FDA electronic reporting form – is used, which is easier to
complete (Saudi Food and Drug Authority, 2013d). An
advanced electronic database, Empirica Trace, is used to col-
lect, store, analyze, and evaluate the reports that come from
pharmaceutical companies, healthcare professionals, patients,
and other reporters. Vigibase is another database that is used
by the pharmacovigilance center at the SFDA (Saeed, 2014). It
belongs to the World Health Organization-Uppsala Monitor-
ing Center (WHO-UMC). It has around 12 million reports
and it helps to perform data mining by the staff of Pharma-
covigilance center to help them in the evaluation process
(Vigibase, 2016). The SFDA is to continue using and evaluat-
ing electronic systems that can help in their daily processes and
tasks.
3.1.6. Pharmacovigilance guidelines
The NPC has to carry out the significant task of implementing
the pharmacovigilance guidelines and subsequently ensuring
that the guidelines are adhered to. The Saudi pharmacovigi-
lance guidelines have been adopted from the ICH volume 9a
guideline, which is also used by the European Medicine
Agency (EMA) (Saudi Food and Drug Authority, 2013e;
Wilbur, 2013). However, the EMA has established a new
guideline that is the Good Pharmacovigilance Practice Guide-
line (Xie and Tian, 2013). As a first step, after introducing the
new European guideline, the VICM established a committee to
review, adopt, and apply it in the KSA. The current guideline
covered all required aspects to apply all pharmacovigilance
activities by regulatory bodies, pharmaceutical companies,
electronic systems, and some information for healthcare pro-
fessionals. Furthermore, the health department at the Council
of the Arab League has decided to have one document on
Good Pharmacovigilance Practice for Arab Countries, which
is also adopted from the EMA guideline with some modifica-
tions. However, the idea of having one guideline for Arab
countries is not the same as the EMA guideline, as the Arab
guideline is not applicable to all countries and each country
could have its own guideline (Saad, 2014). Furthermore, the
SFDA has recently published its own Pharmacovigilance
guidelines, ‘‘Guidelines on Good Pharmacovigilance Prac-
tices,” implemented on September 1, 2015 (Saudi Food and
Drug Authority, 2013f).
3.2. Marketing Authorization Holders (MAHs)
Still within the scope of pharmacovigilance, (MAHs) ensure
the efficient organization of the system of pharmacovigilance
and risk management to ensure that their products are liable
and accountable in the market, and to ensure that appropriate
action can be taken in the market when necessary. Another
important point is to note that MAHs ensure that all informa-
tion pertinent to the risk-benefit balance of a medicinal pro-
duct is reported to the SFDA fully and immediately
according to the legislation that has been formed (Saudi
Food and Drug Authority, 2013f).
In terms of the roles and responsibilities that MAHs have
to bear, one important aspect is to develop a system where they
can gather, collate, and assess pharmacovigilance data. Theytem in Saudi Arabia. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/
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any suspected adverse reactions. They also have to ensure that
they meet the legal obligations with regard to the preparation
and submission of periodic safety update reports. MAHs must
respond whether there are any requests from the SFDA on
additional information that is necessary to evaluate the risks
and benefits of any medicinal product. Their job description
also includes ensuring that the authorization of marketing is
maintained and reflects the most updated information about
the products. MAHs should also assign a person who is qual-
ified to make sure that all these responsibilities are fulfilled
(Saudi Food and Drug Authority, 2013f).
In simple terms, MAHs should be held accountable for
overall pharmacovigilance for all medicinal products for which
the company holds marketing authorizations within Saudi
Arabia. Therefore, most of the MAHs in Saudi Arabia have
started to have a pharmacovigilance department within their
organizational structures. The task of this department is to
make sure that all medications for each MAHs are followed
and to monitor the safety of these medications. Several tasks
are conducted by the qualified person of pharmacovigilance
(QPPV) – the person who is responsible for conducting these
activities – including reporting ADRs, preparing and submit-
ting PSURs and/or risk management plans (RMPs), following
up with any requirements from the SFDA or healthcare
professionals (HCPs) with respect to the safety of their medi-
cations, conducting training for HCPs about pharmacovigi-
lance, and post-marketing safety.
3.3. Health institutions and healthcare professionals
Pharmacovigilance has not been well practiced by hospitals/
clinics in Saudi Arabia. This is due to lack of knowledge
and awareness about pharmacovigilance among the HCPs,
and the lack of follow-ups about ADRs. In addition, the
Ministry of Health (MOH) should encourage and apply phar-
macovigilance activities in its hospitals and clinics. However,
some hospitals within the MOH and other sectors have
started implementing the pharmacovigilance concept. Some
of these hospitals have established a medication safety officer
(MSO) who has a job description similar to the QPPV in
pharmaceutical companies (Aljadhey et al., 2014). The
MSO is responsible to ensure the safety of medications inside
the hospital by applying all policies and procedures that are
set up by the hospital itself or by the SFDA. The MSO also
has an important role in training and educating all HCPs in
their health institutions, as safety of medications is the prime
responsibility of all HCPs. In the hospitals that have this
department, the MSO is located either within the pharmaceu-
tical care department or within the quality department within
the hospital. Regardless of their location, they apply the same
tasks.
HCPs are not well trained or educated in pharmacovigi-
lance and the safety of medications and this could be the rea-
son that these concepts are not taught in most health colleges
(i.e. medicine, pharmacy, nursing, etc.) and that there are not
many training courses on pharmacovigilance in Saudi Arabia
(Aljadhey et al., 2014; Alrwisan et al., 2014; Khan et al.,
2012; Mahmoud et al., 2014). Therefore, there is a need for
considerable efforts to train and educate all HCPs in Saudi
Arabia in pharmacovigilance and medication safety.Please cite this article in press as: Alshammari, T.M. et al., Pharmacovigilance sys
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Patients or even healthy individuals are not currently involved
in the pharmacovigilance or medication safety activities. There
are several reasons for this: first, the HCPs themselves are not
promoting and trained in pharmacovigilance; second, pharma-
ceutical companies do not perform any educational activities
for the wider society with respect to pharmacovigilance and
medication safety; third, there is a lack of patient counseling
in both government and private health institutions. However,
this is a global concern and all stakeholders have to play their
role in raising patient awareness on this issue (Jha et al., 2014).
4. Expert opinion
The pharmacovigilance system in Saudi Arabia is based on the
European system and most of the activities conducted were
taken from the European guidelines and practices. SFDA
provided the required resources to perform the needed
pharmacovigilance activities. Thus, the pharmacovigilance
department performed most of the services; however, there
remain activities still not conducted by the SFDA, such as con-
ducting post marketing safety studies inside Saudi Arabia and
a complete risk management system.
In the future, there is a need for all stakeholders including the
SFDA, pharmaceutical companies, and HCPs to improve their
performance with respect to pharmacovigilance activities. Phar-
maceutical companies have to understand that there is a need for
pharmacovigilance to be implemented in a well-resourced
department to perform the full pharmacovigilance activities.
Also, they should apply the activities based on the SFDA guide-
lines. Furthermore, HCPs have to realize their responsibilities,
as they are the means to detecting ADRs with their patients.
5. Conclusions
Pharmacovigilance is considered a new concept in Saudi
Arabia. However, there are good initiatives being conducted
by some stakeholders, including the SFDA and some pharma-
ceutical companies and hospitals. Nevertheless, there is a need
to enhance the quality of work that has been done to date by
these stakeholders and there is a need for MAHs and HCPs to
play their role with respect to pharmacovigilance and medica-
tion safety. Also, some further actions are suggested such as
having a gateway to facilitate the transmission of ADR reports
and to increase the number and quality of partnership rela-
tions between all stakeholders.
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